Table S1.
Three-month changes (after the ID) in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy in primary care practices in Germany
| Variables | N | Baseline ≤6 months before ID | 3 months after ID | Difference | P-value |
|---|---|---|---|---|---|
| Dapagliflozin monotherapy | |||||
| HbA1c (%) | 72 | 8.1 (1.7) | 7.7 (1.4) | −0.4 (1.2) | 0.010 |
| Body weight (kg) | 24 | 110.0 (27.6) | 105.3 (25.7) | −4.7 (7.5) | <0.001 |
| Systolic blood pressure (mmHg) | 45 | 137.1 (15.3) | 136.0 (18.6) | −1.1 (17.6) | 0.499 |
| Dapagliflozin + metformin | |||||
| HbA1c (%) | 73 | 8.3 (1.6) | 7.7 (1.2) | −0.6 (1.5) | <0.001 |
| Body weight (kg) | 17 | 99.9 (21.4) | 96.7 (22.3) | −3.2 (3.7) | 0.002 |
| Systolic blood pressure (mmHg) | 37 | 135.4 (18.1) | 134.5 (14.8) | −0.9 (20.3) | 0.964 |
| Dapagliflozin + insulin | |||||
| HbA1c (%) | 305 | 8.7 (1.5) | 8.0 (1.2) | −0.8 (1.4) | <0.001 |
| Body weight (kg) | 133 | 105.7 (22.8) | 103.8 (22.5) | −1.9 (5.0) | <0.001 |
| Systolic blood pressure (mmHg) | 223 | 137.0 (17.8) | 135.4 (18.1) | −1.6 (18.1) | 0.070 |
| Dapagliflozin + DPP-4 inhibitors | |||||
| HbA1c (%) | 298 | 8.5 (1.5) | 7.6 (1.1) | −0.9 (1.4) | <0.001 |
| Body weight (kg) | 68 | 96.9 (18.1) | 94.7 (17.0) | −2.1 (3.6) | <0.001 |
| Systolic blood pressure (mmHg) | 128 | 139.0 (18.1) | 135.4 (17.2) | −3.6 (17.0) | 0.018 |
Note: Data are presented as mean (SD). Bold text indicate that the effect is significant.
Abbreviations: DPP-4, dipeptidyl peptidase-4; ID, index date; SD, standard deviation; HbA1c, glycated hemoglobin.